overview  synthetic biologics inc syn pioneering cuttingedge research into clinical science designed to protect and preserve the human gut microbiome menu overview management team board of directors clinical advisors careers overview synthetic biologics is a latestage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients our lead candidates poised for phase  development are  syn ribaxamase which is designed to protect the gut microbiome from the effects of certain commonly used intravenous iv betalactam antibiotics for the prevention of c difficile infection cdi pathogenic overgrowth and the emergence of antimicrobial resistance amr and  syn which is intended to reduce the impact of methane producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation ibsc we are also developing preclinical stage monoclonal antibody therapies for the prevention and treatment of pertussis and novel discovery stage biotherapeutics for the treatment of phenylketonuria pku your browser does not support html video our lead candidates syn ribaxamase ribaxamase is an oral enzyme tablet engineered to survive the stomach thereby allowing iv betalactam antibiotics to treat infection while ribaxamase protects and preserves the naturally occurring gut microbiome from the onset of antibioticmediated primary c difficile infection pathogenic colonization and the emergence antimicrobial resistance view syn ribaxamase syn syn is a proprietary modifiedrelease formulation of lovastatin lactone that is designed to bypass the stomach and reduce the bodys natural methane production in the gi tract to treat an underlying cause of the symptoms associated with irritable bowel syndrome with constipation ibsc view syn protecting the gut microbiome your body has  times as many microbe cells as human cells we’re leveraging the microbiome to radically change today’s medicine watch video how syn ribaxamase works syn is an oral prophylactic therapy designed to degrade residual and still viable iv betalactam antibiotics which pass through the gi tract following systemic circulation watch video how syn works syn is intended to act primarily in the intestinal lumen while avoiding systemic absorption thereby targeting the major cause of ibsc not just the symptoms leadership our experienced management team has an extensive clinical and commercial track record view management team view board of directors view advisors product pipeline  synthetic biologics inc syn product pipeline menu overview syn ribaxamase syn overview our two lead candidates focused on protection and preservation of the gut microbiome are ribaxamase designed to prevent primary c difficile infection cdi and pathogenic overgrowth and the emergence of antimicrobial resistance amr and syn designed to reduce methane production in the gi to treat an underlying cause of irritable bowel syndrome with constipation ibsc our research candidates include monoclonal antibody therapies for the prevention and treatment of pertussis and novel biotherapeutics for the treatment of patients with phenylketonuria pku microbiomefocused pipeline candidate  indication development stage preclinical phase  phase  phase  market syn ribaxamase prevention of cdi pathogenic overgrowth and amr preclinical phase complete phase  phase complete phase  phase in progress phase  phase not started market phase not started syn treatment of ibsc preclinical phase complete phase  phase complete phase  phase in progress phase  phase not started market phase not started syn ribaxamase designed to be coadministered with iv betalactam antibiotics ribaxamase is an oral enzyme tablet that allows the iv antibiotic to treat the infection while protecting the gut microbiome and preventing clostridium difficile infection cdi pathogenic overgrowth and the emergence of antimicrobial resistance amr syn received breakthrough therapy designation from the fda for the prevention of clostridium difficile infection view syn ribaxamase syn syn is a proprietary modifiedrelease formulation of lovastatin lactone that is designed to bypass the stomach and reduce the body’s natural methane production in the gi tract to treat an underlying cause of the symptoms associated with irritable bowel syndrome with constipation ibsc view syn research pipeline candidate  indication research stage discovery preclinical syn pertussis whooping cough discovery phase complete preclinical phase in progress syn phenylketonuria pku discovery phase in progress preclinical phase not started collaborative partners syn through our august  exclusive channel collaboration ecc with intrexon corporation nyse xon and academic researchers at the university of texas at austin ut austin we are developing syn a combination of two humanized antibodies that includes hub for the treatment of critically ill infants with pertussis in addition ut austin was awarded a grant from the gates foundation to generate preclinical proofofconcept data to test the hypothesis that hub antibody administration at birth may also have a role in the prevention of pertussis jennifer maynard phd the principal investigator of the grant at ut austin will test this hypothesis by using our hub antibody syn through our august  ecc with intrexon corporation we are pursuing the development and commercialization of novel biotherapeutics for the treatment of patients with phenylketonuria pku a serious and debilitating metabolic disorder through the ecc we plan to utilize intrexons actobiotics™ platform which is a proprietary method of delivering therapeutic protein and peptides to the gastrointestinal gi tract through foodgrade microbes management team  synthetic biologics inc syn management team menu overview management team board of directors clinical advisors careers jeffrey riley chief executive officer president and director mr riley a member of the synthetic biologics board of directors since march  and chairman of the board from november  to may  was appointed as the company’s president and chief executive officer in february  he has more than  years of experience in the biotechnology and pharmaceutical industries during which he negotiated numerous worldwide strategic corporate alliances established joint ventures and assisted in obtaining venture financings to support product development most recently in addition to serving as synthetic biologics chairman where mr riley played an integral role in the formation of the company¹s recent collaboration with intrexon corporation he served as managing director of  ventures a life sciencefocused venture consulting firm with a commercial and traditional focus prior to this he was a venture partner with qic bioventures fund the life sciencefocused venture component of the  billion australianbased queensland investment corporation qic over his career mr riley held senior positions within the mergers  acquisitions and in country management groups at both smithkline beecham and pfizer additionally he served as cfo and vp corporate development for nichols institute diagnostics later acquired by corning and spun out to quest diagnostics inc nyse dgx mr riley holds a bachelor of science degree from boise state university completed coursework at ucsfberkeley in drug discoverydevelopment and participated in a dualdegree graduate program mbamim sponsored by arizona state university and the thunderbird school of global management steven shallcross chief financial officer treasurer and secretary steven shallcross joined synthetic biologics in june  as chief financial officer treasurer and secretary mr shallcross brings to synthetic biologics operational financial and international biotech industry experience as well as an established track record at leading the financial development and strategy for several publicly traded biotech companies he served for four years as the chief financial officer and treasurer of vanda pharmaceuticals inc leading the company through its successful ipo and followon offering he most recently served as executive vice president and chief financial officer of nuo therapeutics inc and previously served as the senior vice president and chief financial officer of middlebrook pharmaceuticals inc formerly advancis pharmaceutical corporation mr shallcross also served as executive vice president and chief financial officer of innocoll ag formerly privately held innocoll holdings inc a global commercialstage biopharmaceutical company specializing in the development and commercialization of collagen based products in addition to his substantial biotech industry experience mr shallcross also held key leadership positions with a number of other companies including serving as the chief financial officer of empire petroleum partners llc and bering truck corporation and acting chief financial officer for senseonics he holds an mba from the university of chicago’s booth school of business a bachelor of science degree in accounting from the university of illinois chicago and is a certified public accountant in the state of illinois joseph sliman md mph chief medical officer from january   until january   dr sliman served as the company’s senior vice presidentclinical  regulatory affairs dr sliman has more than  years of experience in clinical and public health research including  years directing clinical projects and product development in therapeutic areas such as infectious diseases and vaccines from september  until january  dr sliman served as senior medical director and head of patient safety and pharmacovigilance at vanda pharmaceuticals inc where he directed efforts for a new drug application for hetlioz tasimelteon which is indicated for the treatment of non hour disorder in totally blind adults from december  until august  dr sliman served as medical director in vaccines and infectious diseases at medimmune inc where he was a member of successful biologics licensure application teams prior to joining medimmune inc he served as associate medical director at dynport vaccine company where he was the clinical director for seasonal and pandemic influenza vaccine trials as well as its defense vaccines development program partnered with department of defense joint vaccines acquisition program  during his service in the united states navy dr sliman led the u s pacific fleet disease surveillance programs including influenza surveillance preparedness and prevention as well as communicable disease and injury surveillance and prevention and health policy development dr sliman earned an md from the uniformed services university a master’s degree in public health from the johns hopkins university school of public health and a bs in molecular and cell biology with honors in biology from pennsylvania state university michael kaleko md phd senior vice president research  development dr kaleko senior vice president research  development joined synthetic biologics in march  as the scientific director he brings over  years of experience in the biotechnologypharmaceutical sector including eleven years at genetic therapy inc a novartis company where he developed multiple gene transfer and gene expression platform technologies for hemophilia cancer diabetes and ocular diseases in  he cofounded advanced vision therapies inc to develop treatments for eye diseases including an antiinflammatory biological for multiple ocular indications after selling the company in  he continued as chief scientific officer until  dr kaleko has published  peerreviewed articles filed over  patent applications and received the novartis pharma research and development business excellence award for his work in the diabetes field dr kaleko earned scb md and phd degrees from brown university served his medical residency in internal medicine at vanderbilt university and completed a fellowship in clinical endocrinology with a focus in gene therapy research at the university of washington seattle raymond d stapleton jr phd senior vice president manufacturing raymond d stapleton jr phd joined synthetic biologics in october  as senior vice president manufacturing dr stapleton is a pharmaceutical and biotechnology executive with over  years of experience at merck  co inc in manufacturing operations quality science technology engineering and process development  he most recently served as executive director global vaccine technology and engineering during his tenure at merck dr stapleton contributed to the scale up tech transfer and manufacturing product launch of multiple billion dollar franchises including isentress® oral solid dosage for aids gardasil® hpv vaccine keytruda® antipd cancer mab therapy and performed process development for the cholesterol lowering therapy mevacor® lovastatin dr stapleton earned a phd in microbial ecology from the center for environmental biotechnology at the university of tennessee knoxville and a bs degree in biology from mary washington college subsequently he was the recipient of an alexander hollaender fellowship for postdoctoral studies in the environmental science division at oak ridge national laboratory dr stapleton has served for  years as a member of the journal of industrial microbiology and biotechnology review board and is an ad hoc reviewer for several journals including environmental science and technology antonie von leeuwenhook and enzyme and microbial technology he has coedited a book and coauthored patents as well as several peerreviewed manuscripts and presentations christopher t da costa md phd mba facp vice president clinical development christopher da costa md phd mba facp joined synthetic biologics in january  as vice president clinical development dr da costa brings to synthetic biologics experience in clinical development medical affairs drug safety and regulatory affairs gained in several large pharmaceutical and smaller biotechnology companies he has over  years’ academic and industry experience in multiple therapeutic areas primarily in vaccines and infectious diseases but also including critical care organ transplantation hematology and neuroscience  most recently he served as global medical director clinical development and medical affairs working with asahi kasei pharma america on thrombomodulin as a novel therapy for sepsis and for early allograft dysfunction in liver transplantation additionally he previously served as director of clinical development tuberculosis vaccines with aeras senior medical director infectious diseases with pfizer compound development team leader with janssen alzheimer immunotherapy director of clinical development mmr and varicella vaccines with glaxosmithkline and associate director of regulatory affairs vaccines with merck he also has over  years’ clinical practice experience in hospital medicine infectious diseases wound care and hyperbaric medicine he is a fellow of the american college of physicians and member of the infectious diseases society of america dr da costa gained his undergraduate and medical degrees at the university of zambia masters and phd degrees at the london school of hygiene  tropical medicine uk and physicians’ executive mba at auburn university’s raymond j harbert college of business deb mathews pharmd vice president medical affairs deb mathews pharmd joined synthetic biologics in may  as vice president medical affairs in this newly created position she will be responsible for all medical affairsrelated activities with a focus on supporting latestage clinical development for the companys two lead gi microbiomefocused drug candidates dr mathews is a pharmaceutical and biotechnology executive with over  years of clinical and medical affairs experience with specialized therapeutic focus in both infectious disease and oncology most recently she served as executive medical science lead at bayer healthcare pharmaceuticals inc prior to this dr mathews served in various strategic medical affairs leadership roles at novartis astrazeneca tibotec therapeutics and glaxosmithkline inc dr mathews received a doctorate of pharmacy degree from florida am university her credentials also include hiv specialist certification from the american academy of hiv medicine and membership with the american society of microbiology disclaimer  synthetic biologics inc syn disclaimer the information in this website contains forwardlooking statements within the meaning of section a of the securities act of  as amended and section e of the securities and exchange act of  as amended on synthetic biologics current expectations and projections about future events in some cases forwardlooking statements can be identified by terminology such as may should potential continue could  expects anticipates intends plans believes estimates and similar expressions these statements are based upon current beliefs expectations and assumptions and are subject to a number of risks and uncertainties many of which are difficult to predict and include statements regarding the timing and results of our clinical trials and our ability to successfully develop products with superior benefits the forwardlooking statements are subject to risks and uncertainties that could cause actual results to differ materially from those set forth or implied by any forwardlooking statements important factors that could cause actual results to differ materially from those reflected in synthetic biologics forwardlooking statements include among others the availability of financial and other resources and the allocation of resources among different potential uses a failure of our clinical trials to be completed on time or to achieve desired results or failure by us or our strategic partners to successfully commercialize products and other factors described in greater detail on synthetic biologics report on form k and other filings with the sec which are available at wwwsecgov as with all material posted on this website such forwardlooking statements are current as of the date posted and synthetic biologics expressly disclaims any obligation to update such statements all statements and expressions are the sole opinion of the company and are subject to change without notice  the company is not liable for any investment decisions by its readers or subscribers  it is strongly recommended that any purchase or sale decision be discussed with a financial advisor or a brokerdealer or a member of any financial regulatory bodies  the information contained herein has been provided as an information service only  the accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained  links to third party pages are provided for convenience only synthetic biologics does not express any opinion on the content of any third party pages and expressly disclaims any liability for all third party information and the use of such information investors are cautioned that they may lose all or a portion of their investment in this or any other company synthetic biologics inc syn protecting the gut microbiome synthetic biologics is pioneering cuttingedge microbiome science designed to preserve the microbiome to protect and restore the health of patients our two lead programs in latestage clinical development are syn ribaxamase deigned to protect the natural gut microbiome to prevent antibioticmediated primary c difficile infection cdi pathogenic overgrowth and the emergence of antimicrobial resistance amr and syn designed to treat an underlying cause of irritable bowel syndrome with constipation ibsc view syn ribaxamase view syn about synthetic biologics we are a latestage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients learn more leadership our experienced management team has an extensive clinical and commercial track record view management team view board of directors view advisors latest news jul   • am edt synthetic biologics to report second quarter  operational highlights and financial results on august    conference call scheduled for thursday august   at  am edt  rockville md july   prnewswire   view all news in the news may   mining microbes creating genomic tools to fight disease view all in the news investor relations symbol nyse american syn price change volume day lowhigh  week lowhigh investor relations view sec filings annual meeting materials  synthetic biologics inc syn annual meeting materials menu overview news  events press releases ir calendar email alerts company information profile presentations management team contacts analyst coverage faq financial information financials financial results stock data quote charts historical data sec filings all sec filings annual reports quarterly reports section  filings corporate governance board of directors board committees governance documents quick links email alerts tear sheet contacts rss news feed  annual meeting  annual report  proxy statement stockscountryunited states index  markets index bulletin investor alert stocks rates funds bonds benchmarks real estate investment trusts futures american depository receipt stocks exchange traded notes warrants indexes exchange traded funds currencies crypto currencies location united states name exchange sector  communique laboratory inc ocqlf ootc software  property insurance holdings inc pih xnas nonlife insurance flowerscom inc cl a flws xnas specialty retail pm industries inc opmz ootc food products st capital bank ca fisb ootc banking st constitution bancorp fccy xnas banking st nrg corp fnrc ootc oil extraction st source corp srce xnas banking  motors inc etfm ootc automobiles st century fox inc cl a foxa xnas broadcasting st century fox inc cl b fox xnas broadcasting vianet group inc adr vnet xnas internetonline nd century group inc xxii xase biotechnology  kid doc inc tvmd ootc healthcare provision u inc twou xnas software xleveraged long etracs linked to wells fargo business development co index  bdcl arcx major international banks xleveraged long etracs wells fargo business development lbdc arcx major international banks d eye solutions inc tdey ootc motion picturesound recording d pioneer systems inc dpsm ootc software d systems corp ddd xnys computersconsumer electronics dicon corp tdcp ootc software dshoppingcom thds ootc mixed retailing dx industries inc dddx ootc computersconsumer electronics i group plc adr tgopy ootc finance companies m co mmm xnys diversified holding companies pea international inc tpnl xotc accounting power energy group inc pspw ootc renewable energy generation tl technologies corp ttmzf ootc advertisingmarketingpublic relations  property management inc ftpm ootc real estate agentsbrokers cable tv international inc catv ootc diversified business services licensing corp fourq ootc diversified business services com ltd adr wbai xnys gambling industries job inc adr jobs xnas employmenttraining services com inc adr wuba xnys consumer services barz international inc barz ootc networking n plus inc fplsf ootc commodity chemicals d global technologies inc sixd ootc computer services  renewable energy corp rnwr ootc multiutilities  energy ltd adr tngry ootc oil extraction  holdings plc eihdf ootc gambling industries point energy partners lp cafd xnas renewable energy generation x inc eght xnas wired telecommunications services a clean slate inc drwn ootc diversified business services aw revenue royalties income fund awrrf ootc restaurants a h belo corp series a ahc xnys publishing a schulman inc shlm xnas commodity chemicals a schulman inc  pfd slmnp ootc commodity chemicals ad makepeace co make ootc farming am castle  co cas xnys wholesalers ao smith corp aos xnys building materialsproducts ap moellermaersk as adr amkby ootc water transportshipping ap moellermaersk as series a amkaf ootc water transportshipping ap moellermaersk as series b amkbf ootc water transportshipping as roma spa asraf ootc recreational services a group inc awon ootc tobacco a networks inc aten xnys computer services a milk co ltd acopf ootc biotechnology aac holdings inc aac xnys healthcare provision aac technologies holdings inc aacaf ootc industrial electronics aac technologies holdings inc adr aacay ootc industrial electronics aaon inc aaon xnas building materialsproducts aap inc aapj ootc food products aar corp air xnys aerospace productsparts aarons inc aan xnys consumer services ab science sa abscf ootc pharmaceuticals ab svensk exportkredit elements linked to mlcx biofuels index total return fue arcx finance companies ab svensk exportkredit elements linked to mlcx grain index total return gru arcx finance companies abt financial corp abto ootc banking abacus mining  exploration corp abcff ootc general mining abakan inc abki ootc industrial products abattis bioceuticals corp attbf ootc biotechnology abaxis inc abax xnas medical equipmentsupplies abb ltd ablzf ootc industrial machinery abb ltd adr abb xnys industrial machinery abbott laboratories abt xnys pharmaceuticals abbvie inc abbv xnys biotechnology abby inc abby ootc oil extraction abcam plc abczf ootc biotechnology abcam plc adr abczy ootc biotechnology abco energy inc abce ootc industrial machinery abcourt mines inc abmbf ootc general mining aben resources ltd abnaf ootc general mining abengoa sa b agoaf ootc construction abeona therapeutics inc abeo xnas biotechnology abeona therapeutics inc wt abeow xnas abercrombie  fitch co anf xnys clothing retail aberdeen asiapacific income fund inc fax xase closedend funds aberdeen asiapacific income investment co ltd abakf ootc closedend funds aberdeen asset management plc abdnf ootc investment advisors aberdeen asset management plc adr abdny ootc investment advisors aberdeen australia equity fund inc iaf xase closedend funds aberdeen chile fund inc ch xase closedend funds aberdeen emerging markets smaller company opportunities fund inc abe xase closedend funds aberdeen global income fund inc fco xase closedend funds aberdeen greater china fund inc gch xnys closedend funds aberdeen indonesia fund inc if xase closedend funds aberdeen international inc aabvf ootc general mining aberdeen israel fund inc isl xase closedend funds aberdeen japan equity fund inc jeq xnys closedend funds aberdeen latin america equity fund inc laq xase closedend funds aberdeen singapore fund inc sgf xnys closedend funds abertis infraestructuras sa adr abrty ootc transportation services ability inc abil xnas precision products ability inc wt abiwf ootc abiomed inc abmd xnas medical equipmentsupplies abitibi royalties inc atbyf ootc general mining able energy inc able ootc gas utilities ablynx nv ablyf ootc biotechnology abm industries inc abm xnys diversified business services abraxas petroleum corp axas xnas oil extraction absecon bancorp ascn ootc banking absolute health  fitness inc ahfi ootc recreational services absolute software corp alswf ootc software abt holdings inc abot ootc precious metals abtech holdings inc abhd ootc industrial machinery abv consulting inc abvn ootc advertisingmarketingpublic relations ac immune sa aciu xnas biotechnology acacia communications inc acia xnas networking acacia diversified holdings inc acca ootc specialty retail acacia mining plc abglf ootc gold acacia research corp  acacia technologies actg xnas diversified business services acadia healthcare co inc achc xnas healthcare provision acadia pharmaceuticals inc acad xnas biotechnology acadia realty trust akr xnys acadian timber corp acazf ootc forestry  wood products acasti pharma inc acst xnas pharmaceuticals accelera innovations inc acnv ootc healthcare provision accelerate diagnostics inc axdx xnas biotechnology accelerize inc aclz xotc life insurance acceleron pharma inc xlrn xnas biotechnology accenture plc cl a acn xnys diversified business services access national corp ancx xnas banking access power inc accr ootc wired telecommunications services access worldwide communications inc awwc ootc advertisingmarketingpublic relations acciona sa acxif ootc construction acco brands corp acco xnys nondurable household products accor sa acrff ootc hotels accor sa adr accyy ootc hotels accordia golf co ltd acgff ootc recreational services accredited mortgage loan reit trust  perp cum pfd series a ahhap ootc mortgages accretive health inc achi ootc healthcare provision accuray inc aray xnas medical equipmentsupplies accuride corp acw xnys auto  commercial vehicle parts acelrx pharmaceuticals inc acrx xnas pharmaceuticals acer inc gdr reg s aceyy ootc computersconsumer electronics acerus pharmaceuticals corp trlpf ootc biotechnology aceto corp acet xnas specialty chemicals achaogen inc akao xnas biotechnology achillion pharmaceuticals inc achn xnas biotechnology aci worldwide inc aciw xnas software «» log in  pm edt july   marketstatecountryus new york after marketstatecountryuk london closed marketstatecountryjp tokyo closed marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest pthe dark side of cruises pthe highest paid athletes in the world in one chart poj simpson made over  while in prison and won’t have to give any of it to the goldman family p trump to police dont be too nice phere are  coworkers you should avoid like the plague — especially in meetings ptop  most annoying people you may want to unfriend on facebook pthis is one person you should never unfriend on facebook p horrible ways typos could alter the course of your life ppaint your bathroom this color and boost your home’s selling price by  pamericans’ new badge of honor ‘i was blocked by a celebrity’ p weird things i found out about america in my first  hours pbeyond tesla  stocks driving the autonomous car revolution pthese  highly taxed companies need congress to finally act on tax reform pwatch out ‘kids’ are making the most money in this stock market p real ways for millennials to save money not by brownbagging and skipping starbucks p‘game of thrones’ this computer model predicts who will be killed off — or survive pthis basic balanced index fund is beating the hedge fund averages phere’s one trump fan who might make you some money pwhy it might be time to invest in the companies amazon is destroying pbitcoin investors things may get very ugly soon if this chart overlay is right loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice  events  synthetic biologics inc syn events menu overview press releases events in the news scientific publications upcoming events second quarter  operational highlights and financial results conference call august   •  am edt webcast us toll free international   the international conferences on the molecular biology and pathogenisis of the clostridia  clospath august –august   ann arbor mi annual conference on antimicrobials and drug resistance august –august   toronto ontario canada  annual meeting of stockholders september   •  am edt proxy statement third annual world antimicrobial resistance congress september –september   washington dc infectious disease week idsa  october –october   san diego ca japan digestive disease week  jddw october –october   fukuoka japan st world hospital congeress – international hospital federation ihf  november –november   tapei taiwan c diff foundation th annual international raising c diff awareness conference  health expo november –november   las vegas nv european microbiome congress november –november   london uk past events microbiome drug development summit june –june   boston ma bio international convention  june –june   san diego ca association for professionals in infection control and epidemiology apic  june –june   portland or american society for microbiology asm  june –june   new orleans la flagship sponsored boston ceo meeting may –may   boston ma c diff spores  more radio show with nancy c caralla protecting the gut microbiome a paradigm shift in managing gi disorders featuring joseph sliman md may   may    click here to listen digestive disease week ddw  may –may   chicago il first quarter  operational highlights and financial results conference call may   •  pm edt webcast related documents  quarterly results pdf release audiowebcast pdf html q filing zip xls html xbrl european congress of clinical microbiology and infectious diseases eccmid  april –april   vienna austria rd annual translational microbiome conference april –april   boston ma shea  spring conference march –march   st louis mo asm innovative microbial ecology for mitigation of antibiotic resistance and bacterial diseases march –march   crystal city va bioeurope spring march –march   barcelona spain smi superbugs  superdrugs  annual conference march –march   london uk smi interviews joe sliman cmo of synthetic biologics th annual roth conference march   •  am pdt the ritzcarlton laguna niguel dana point ca webcast fourth quarter  operational highlights and financial results conference call march   •  pm edt webcast related documents  quarterly results pdf release audiowebcast pdf html k filing zip xls html xbrl  bio ceo  investor conference february   •  pm edt waldorf astoria new york ny webcast more past events » syn stock price  synthetic biologics inc stock quote us nyse american  marketwatch sections watchlist signup • login search bulletin us europe asia fx rates futures range d d m m m y y dow    sp     nasdaq    globaldow    gold    oil    sp  movers algn  mhk  col  lyb  fls  mo  sbux  gt  latest newsall times eastern p updated the dark side of cruises p trump to police dont be too nice p updated the highest paid athletes in the world in one chart p updated oj simpson made over  while in prison and won’t have to give any of it to the goldman family p updated here are  coworkers you should avoid like the plague — especially in meetings p updated top  most annoying people you may want to unfriend on facebook p updated this is one person you should never unfriend on facebook p updated  horrible ways typos could alter the course of your life p updated paint your bathroom this color and boost your home’s selling price by  p updated americans’ new badge of honor ‘i was blocked by a celebrity’ to be replaced home investing quotes stocks united states syn overview compare quotes stock screener earnings calendar sectors syn us nyse american join td ameritrade find a broker synthetic biologics inc watchlist createsynalert after hours last updated jul    pm edt delayed quote     after hours volume  close chg chg     advanced charting d d m m m ytd y y all   vol advanced charting  vs avg volume k  day avg  m open  close   day lowhigh  day range   week lowhigh  your watchlist customize marketwatch have watchlists log in to see them here or sign up to get started create account … or log in symbol last chg chg  no items in watchlist there are currently no items in this watchlist add ticker to watchlist go to your watchlist no saved watchlists create a list of the investments you want to track create watchlist …or try this starter list uh oh something went wrong while loading watchlist go to watchlist recently viewed tickers no recent tickers visit a quote page and your recently viewed tickers will be displayed here search tickers overview profile news charts financials historical quotes analyst estimates options sec filings insiders key data open  day range     week range    market cap m shares outstanding m public float m beta  rev per employee na pe ratio na eps  yield na dividend na exdividend date na short interest m   of float shorted  average volume m performance  day   month   month  ytd   year  recent news marketwatch other dow jones wednesday’s biggest gaining  declining stocks nov   at  pm et by kate gibson adeona pharmaceuticals shares down  dec   at  am et by nick godt wednesdays biggest gaining and declining stocks apr   at  pm et by marketwatch adeona soars molecular insight retreats apr   at  pm et by val brickates kennedy adeona in spotlight indices sluggish apr   at  am et by val brickates kennedy monsanto’s shares engineered for growth jan   at  am et on barrons cfo moves penske automotive group iconix brand group agenus jun   at  pm et on the wall street journal up and down the ladder the latest comings and goings at pfizer gilead and… may   at  am et on the wall street journal biotechexec exits hurt more than the chemistry may   at  am et on barrons synthetic biologics set for catalysts mar   at  am et on barrons best buy swings to a loss gucci accuses guess of design knockoffs trademark squatting in china irks us retailers mar   at  am et on the wall street journal tpg sizes up surfwear specialist billabong feb   at  pm et on the wall street journal recent news other news press releases synthetic bio nabs us patent covering lead product candidate syn shares ahead  premarket synthetic bio nabs us patent covering lead product candidate syn shares ahead  premarket jun   at  am et on seeking alpha synthetic biologics inc syn makes further ip progress synthetic biologics inc nysemktsyn announced this morning that the us patent and trademark office uspto  jun   at  am et on smarteranalyst can the uptrend continue for synthetic biologics syn investors certainly have to be happy with synthetic biologics inc syn and its short term performance may   at  am et on zackscom synthetic biologics inc syn cuts through the red tape with big fda win for ribaxamase synthetic biologics inc nysemktsyn shares were rising almost  yesterday as the news took off  may   at  am et on smarteranalyst here’s why synthetic biologics inc syn shares skyrocket today nbsp investors in synthetic biologics inc nysemktsyn should be smiling from ear to ear today  may   at  am et on smarteranalyst synthetic bios ribaxamase a breakthrough therapy for prevention of c diff infection shares ahead  premarket synthetic bios ribaxamase a breakthrough therapy for prevention of c diff infection shares ahead  premarket may   at  am et on seeking alpha synthetic biologics syn ceo jeff riley on q  results  earnings call transcript synthetic biologics syn ceo jeff riley on q  results  earnings call transcript may   at  pm et on seeking alpha q synthetic biologics inc q synthetic biologics inc may   at  pm et on edgar online  edg  q k synthetic biologics syn presents at th annual roth conference mar   at  pm et on seeking alpha forget gilead buy these smallcap biotech stocks instead mar   at  pm et on zackscom synthetic biologics syn ceo jeffrey riley on q  results  earnings call transcript mar   at  pm et on seeking alpha msdc management lp buys yahoo coty novagold resources sells hrg group citigroup  feb   at  am et on gurufocuscom synthetic biologics syn investor presentation  slideshow feb   at  pm et on seeking alpha synthetic bio firms up ibsc trial design for lead product candidate syn shares ahead  after hours jan   at  pm et on seeking alpha synthetic biologics positive phase b results will move the needle jan   at  pm et on seeking alpha synthetic bios colead product candidate successful in midstage study shares ahead  premarket jan   at  am et on seeking alpha synthetic bio closes equity offering nov   at  pm et on seeking alpha ampliphi biosciences sweetens followon offering terms nov   at  pm et on seeking alpha could trump tax cut plans republican congress spur biotech ma nov   at  pm et on investors business daily which four biotechs are derisked buyable ahead of election day nov   at  pm et on investors business daily synthetic biologics to report second quarter  operational highlights and financial results on august   synthetic biologics to report second quarter  operational highlights and financial results on august   jul   at  am et on pr newswire  prf synthetic biologics announces allowance of key us patent covering syn intended for the novel treatment of irritable bowel syndrome with constipation ibsc synthetic biologics announces allowance of key us patent covering syn intended for the novel treatment of irritable bowel syndrome with constipation ibsc jun   at  am et on pr newswire  prf todays research reports on stocks to watch quantum corporation and synthetic biologics todays research reports on stocks to watch quantum corporation and synthetic biologics may   at  am et on accesswire blog coverage synthetic biologics wins breakthrough therapy designation for its clostridium difficile infection candidate blog coverage synthetic biologics wins breakthrough therapy designation for its clostridium difficile infection candidate may   at  am et on accesswire synthetic biologics reports first quarter  operational highlights and financial results synthetic biologics reports first quarter  operational highlights and financial results may   at  pm et on pr newswire  prf synthetic biologics to report first quarter  operational highlights and financial results on may   apr   at  pm et on pr newswire  prf synthetic biologics reports preclinical data demonstrating syn provides protection from pertussis in neonatal animal study apr   at  am et on pr newswire  prf research reports initiation on biotech stocks  sangamo eyegate pharma synthetic biologics and regulus mar   at  am et on pr newswire  prf synthetic biologics to present at the th annual roth conference mar   at  am et on pr newswire  prf synthetic biologics reports  year end operational highlights and financial results mar   at  pm et on pr newswire  prf synthetic biologics to report  year end operational highlights and financial results on march   feb   at  pm et on pr newswire  prf technical reports on biotech stocks  progenics pharma intrexon synthetics biologics and nd century feb   at  am et on pr newswire  prf synthetic biologics to present at the  bio ceo  investor conference feb   at  am et on pr newswire  prf synthetic biologics confirms key features of pivotal phase b trial of syn pursuant to consultations with fda jan   at  pm et on pr newswire  prf synthetic biologics syn ribaxamase achieves primary endpoint in phase b trial for c difficile infection cdi jan   at  am et on pr newswire  prf research reports initiation on biotech stocks  arrowhead pharma intracellular therapies synthetic biologics and colucid pharma jan   at  am et on pr newswire  prf synthetic biologics to present at the biotech showcase™  conference jan   at  am et on pr newswire  prf synthetic biologics announces granting of us composition of matter patent for syn designed for the treatment and prevention of pertussis whooping cough dec   at  am et on pr newswire  prf synthetic biologics announces participation in two upcoming investor conferences dec   at  am et on pr newswire  prf synthetic biologics announces closing of public offering of common stock and warrants nov   at  am et on pr newswire  prf synthetic biologics inc synthetic biologics inc is a clinical stage company which engages in the development of therapeutics to preserve the microbiome to protect and restore the health of patients its product portfolio includes syn and syn the syn which is intended to reduce the impact of methaneproducing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation the syn which is designed to protect the gut microbiome from the effects of certain commonly used intravenous iv antibiotics for the prevention of c difficile infection antibioticassociated diarrhea and the emergence of antimicrobial resistance the company was founded by steven h kanzer in january  and is headquartered in rockville md see full profile analyst ratings sell under hold over buy number of ratings  full ratings  biotechs with binary events coming this year jan   at  pm et on benzingacom competitors name chg  market cap biogen inc  b momenta pharmaceuticals inc  b astrazeneca plc adr  b abbott laboratories  b pfizer inc  b competitor data provided by partner content trending tickers powered by dvax  mo  clvs  ssti  imgn  advanced search stocks columns authors topics no results found video center learn morestoryful a division of news corp which owns marketwatch is a leading social media services company headquartered in dublin ireland storyful combines world class journalism with industryleading technology to discover verify and acquire original content and provide the ontheground sources news and media organizations need to tell the stories that matter to their audience flashratings  about us facebook autocomplete demo post a rating  month price target   trending sign up log in flashratings  all research for my stocks the most comprehensive equity research coverage available online never miss a single piece of research upgrade downgrade or target price change by any analyst firm on any stock equity research by professional analysts  especially their rationales more than their forecasts  contains far more interesting and important information about the actual fundamentals of the traded companies than can be gathered from conventional news reports our mission is to unlock access to valuable research on stocks for all retail investors professionals institutions take advantage of our costeffective subscriptions to have flashratingss comprehensive realtime feed delivered into your intranet and trading floor platforms institutional subscriptions websites become a content licensing partner and display flashratingss popular news feed on your website content licensing advertisers advertise with us and have flashratings readers with attractive demographics take advantage of your products advertising investor relations  synthetic biologics inc syn investor relations menu overview news  events press releases ir calendar email alerts company information profile presentations management team contacts analyst coverage faq financial information financials financial results stock data quote charts historical data sec filings all sec filings annual reports quarterly reports section  filings corporate governance board of directors board committees governance documents quick links email alerts tear sheet contacts rss news feed latest news jul   synthetic biologics to report second quarter  operational highlights and financial results on august   read press release upcoming event august   • am edt second quarter  operational highlights and financial results conference call webcast latest financial results q  quarterly results mar   pdf html release audio earnings webcast pdf html q filing html financials zip xls html xbrl sign up for email alertssign up today investor relations symbol nyse american syn price change volume day lowhigh  week lowhigh overview synthetic biologics inc nyse mkt syn is a latestage clinical company developing therapeutics focused on the gut microbiome the companys lead candidates poised for phase  development are  syn which is intended to reduce the impact of methane producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation ibsc and  syn ribaxamase which is designed to protect the gut microbiome from the effects of certain commonly used intravenous iv betalactam antibiotics for the prevention of c difficile infection antibioticassociated diarrhea aad and the emergence of antibioticresistant organisms the company is also developing preclinical stage monoclonal antibody therapies for the prevention and treatment of pertussis and novel discovery stage biotherapeutics for the treatment of phenylketonuria pku view profile leadership our experienced management team holds an extensive clinical and commercial track record view management team view board of directors view advisors investor relations synthetic biologics inc investor relations department t   infosyntheticbiologicscom transfer agent corporate stock transfer inc  cherry creek drive south  denver co  t   investor relations  synthetic biologics inc syn investor relations menu overview news  events press releases ir calendar email alerts company information profile presentations management team contacts analyst coverage faq financial information financials financial results stock data quote charts historical data sec filings all sec filings annual reports quarterly reports section  filings corporate governance board of directors board committees governance documents quick links email alerts tear sheet contacts rss news feed latest news jul   synthetic biologics to report second quarter  operational highlights and financial results on august   read press release upcoming event august   • am edt second quarter  operational highlights and financial results conference call webcast latest financial results q  quarterly results mar   pdf html release audio earnings webcast pdf html q filing html financials zip xls html xbrl sign up for email alertssign up today investor relations symbol nyse american syn price change volume day lowhigh  week lowhigh overview synthetic biologics inc nyse mkt syn is a latestage clinical company developing therapeutics focused on the gut microbiome the companys lead candidates poised for phase  development are  syn which is intended to reduce the impact of methane producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation ibsc and  syn ribaxamase which is designed to protect the gut microbiome from the effects of certain commonly used intravenous iv betalactam antibiotics for the prevention of c difficile infection antibioticassociated diarrhea aad and the emergence of antibioticresistant organisms the company is also developing preclinical stage monoclonal antibody therapies for the prevention and treatment of pertussis and novel discovery stage biotherapeutics for the treatment of phenylketonuria pku view profile leadership our experienced management team holds an extensive clinical and commercial track record view management team view board of directors view advisors investor relations synthetic biologics inc investor relations department t   infosyntheticbiologicscom transfer agent corporate stock transfer inc  cherry creek drive south  denver co  t   profile  synthetic biologics inc syn profile menu overview news  events press releases ir calendar email alerts company information profile presentations management team contacts analyst coverage faq financial information financials financial results stock data quote charts historical data sec filings all sec filings annual reports quarterly reports section  filings corporate governance board of directors board committees governance documents quick links email alerts tear sheet contacts rss news feed business description synthetic biologics is a latestage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients our lead candidates poised for phase  development are  syn ribaxamase which is designed to protect the gut microbiome from the effects of certain commonly used intravenous iv betalactam antibiotics for the prevention of c difficile infection cdi pathogenic overgrowth and the emergence of antimicrobial resistance amr and  syn which is intended to reduce the impact of methane producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation ibsc we are also developing preclinical stage monoclonal antibody therapies for the prevention and treatment of pertussis and novel discovery stage biotherapeutics for the treatment of phenylketonuria pku company info address medical center drivesuite rockville md  us telephone  fax  emailinfosyntheticbiologicscom industry classifications sectorhealthcare industrybiotechnology sicpharmaceutical preparations  stocks index  markets index bulletin investor alert stocks rates funds bonds benchmarks real estate investment trusts futures american depository receipt stocks exchange traded notes warrants indexes exchange traded funds currencies crypto currencies browse stocks stocks az abcdefghijklmnopqrstuvwxyzother browse by location argentina australia austria bahamas bahrain belgium bermuda botswana brazil british virgin islands canada cayman islands chile china colombia curacao cyprus czech republic denmark egypt estonia finland france germany gibraltar greece hong kong hungary iceland india indonesia ireland isle of man israel italy japan jordan kazakhstan kuwait latvia lebanon liechtenstein lithuania luxembourg malaysia malta mauritius mexico monaco money rates morocco namibia netherlands new zealand norway oman pakistan panama peru philippines poland portugal qatar romania russia saudi arabia singapore slovakia slovenia south africa south korea spain sri lanka sweden switzerland taiwan thailand tunisia turkey ukraine united arab emirates united states venezuela western samoa log in  pm edt july   marketstatecountryus new york after marketstatecountryuk london closed marketstatecountryjp tokyo closed marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest pthe dark side of cruises pthe highest paid athletes in the world in one chart poj simpson made over  while in prison and won’t have to give any of it to the goldman family p trump to police dont be too nice phere are  coworkers you should avoid like the plague — especially in meetings ptop  most annoying people you may want to unfriend on facebook pthis is one person you should never unfriend on facebook p horrible ways typos could alter the course of your life ppaint your bathroom this color and boost your home’s selling price by  pamericans’ new badge of honor ‘i was blocked by a celebrity’ p weird things i found out about america in my first  hours pbeyond tesla  stocks driving the autonomous car revolution pthese  highly taxed companies need congress to finally act on tax reform pwatch out ‘kids’ are making the most money in this stock market p real ways for millennials to save money not by brownbagging and skipping starbucks p‘game of thrones’ this computer model predicts who will be killed off — or survive pthis basic balanced index fund is beating the hedge fund averages phere’s one trump fan who might make you some money pwhy it might be time to invest in the companies amazon is destroying pbitcoin investors things may get very ugly soon if this chart overlay is right loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice  stocks index  markets index bulletin investor alert stocks rates funds bonds benchmarks real estate investment trusts futures american depository receipt stocks exchange traded notes warrants indexes exchange traded funds currencies crypto currencies browse stocks stocks az abcdefghijklmnopqrstuvwxyzother browse by location argentina australia austria bahamas bahrain belgium bermuda botswana brazil british virgin islands canada cayman islands chile china colombia curacao cyprus czech republic denmark egypt estonia finland france germany gibraltar greece hong kong hungary iceland india indonesia ireland isle of man israel italy japan jordan kazakhstan kuwait latvia lebanon liechtenstein lithuania luxembourg malaysia malta mauritius mexico monaco money rates morocco namibia netherlands new zealand norway oman pakistan panama peru philippines poland portugal qatar romania russia saudi arabia singapore slovakia slovenia south africa south korea spain sri lanka sweden switzerland taiwan thailand tunisia turkey ukraine united arab emirates united states venezuela western samoa log in  pm edt july   marketstatecountryus new york after marketstatecountryuk london closed marketstatecountryjp tokyo closed marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest pthe dark side of cruises pthe highest paid athletes in the world in one chart poj simpson made over  while in prison and won’t have to give any of it to the goldman family p trump to police dont be too nice phere are  coworkers you should avoid like the plague — especially in meetings ptop  most annoying people you may want to unfriend on facebook pthis is one person you should never unfriend on facebook p horrible ways typos could alter the course of your life ppaint your bathroom this color and boost your home’s selling price by  pamericans’ new badge of honor ‘i was blocked by a celebrity’ p weird things i found out about america in my first  hours pbeyond tesla  stocks driving the autonomous car revolution pthese  highly taxed companies need congress to finally act on tax reform pwatch out ‘kids’ are making the most money in this stock market p real ways for millennials to save money not by brownbagging and skipping starbucks p‘game of thrones’ this computer model predicts who will be killed off — or survive pthis basic balanced index fund is beating the hedge fund averages phere’s one trump fan who might make you some money pwhy it might be time to invest in the companies amazon is destroying pbitcoin investors things may get very ugly soon if this chart overlay is right loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice  syn key statistics  synthetic biologics inc financial ratios  marketwatch bulletin investor alert expand keep open close expand keep open close expand keep open close expand keep open close expand keep open close synthetic biologics inc nyse american syn go set alerts find a broker join td ameritrade market index overview profile news charts financials historical quotes analyst estimates options sec filings insiders marketstatecountryus synthetic biologics inc after hours  quotes are delayed by  min jul    pm syn quoteszigmancomposite   change   volume volume  quotes are delayed by  min quoteszigmancomposite todays close     change   day low day high    week low  week high   company description synthetic biologics inc is a clinical stage company which engages in the development of therapeutics to preserve the microbiome to protect and restore the health of patients its product portfolio includes syn and syn the syn which is intended to reduce the impact of methaneproduci synthetic biologics inc is a clinical stage company which engages in the development of therapeutics to preserve the microbiome to protect and restore the health of patients its product portfolio includes syn and syn the syn which is intended to reduce the impact of methaneproducing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation the syn which is designed to protect the gut microbiome from the effects of certain commonly used intravenous iv antibiotics for the prevention of c difficile infection antibioticassociated diarrhea and the emergence of antimicrobial resistance the company was founded by steven h kanzer in january  and is headquartered in rockville md valuation pe current  pe ratio with extraordinary items  price to book ratio  enterprise value to ebitda  efficiency income per employee  liquidity current ratio  quick ratio  cash ratio  profitability return on assets  return on equity  return on total capital  return on invested capital  capital structure officers and executives name age officer since title mr jeffrey lucero riley   president chief executive officer  director mr steven a shallcross   chief financial officer secretary  treasurer dr klaus gottlieb   vice presidentclinical  regulatory affairs dr joseph sliman   chief medical officer dr deb mathews   vice presidentmedical affairs insider actions – purchase – sale  – number of transactions  date name shares transaction value  jeffrey j kraws director    derivativenonderivative trans at  per share   scott l tarriff director    award at  per share   charles evan ballantyne chief financial officer    acquisition at  per share   steven h kanzer    disposition at  per share   steven h kanzer    disposition at  per share   jeffrey lucero riley ceo and president director    acquisition at  per share   jeffrey lucero riley ceo and president director    acquisition at  per share   jeffrey lucero riley ceo and president director    acquisition at  per share   jeffrey lucero riley ceo and president director    acquisition at  per share   jeffrey lucero riley ceo and president director    acquisition at  per share  newslatestcompanyussyn marketwatch news on syn wednesday’s biggest gaining  declining stocks  pm nov    kate gibson adeona pharmaceuticals shares down   am dec    nick godt wednesdays biggest gaining and declining stocks  pm april    marketwatch adeona soars molecular insight retreats  pm april    val brickates kennedy adeona in spotlight indices sluggish  am april    val brickates kennedy newsnonmarketwatchcompanyussyn other news on syn synthetic bio nabs us patent covering lead product candidate syn shares ahead  premarket  am june    seeking alpha can the uptrend continue for synthetic biologics syn  am may    zackscom synthetic bios ribaxamase a breakthrough therapy for prevention of c diff infection shares ahead  premarket  am may    seeking alpha synthetic biologics syn ceo jeff riley on q  results  earnings call transcript  pm may    seeking alpha q synthetic biologics inc  pm may    edgar online  edg  q k synthetic biologics syn presents at th annual roth conference  pm march    seeking alpha forget gilead buy these smallcap biotech stocks instead  pm march    zackscom synthetic biologics syn ceo jeffrey riley on q  results  earnings call transcript  am march    seeking alpha msdc management lp buys yahoo coty novagold resources sells hrg group citigroup   am feb    gurufocuscom synthetic biologics syn investor presentation  slideshow  pm feb    seeking alpha synthetic bio firms up ibsc trial design for lead product candidate syn shares ahead  after hours  pm jan    seeking alpha synthetic biologics positive phase b results will move the needle  pm jan    seeking alpha synthetic bios colead product candidate successful in midstage study shares ahead  premarket  am jan    seeking alpha synthetic bio closes equity offering  pm nov    seeking alpha ampliphi biosciences sweetens followon offering terms  pm nov    seeking alpha could trump tax cut plans republican congress spur biotech ma  pm nov    investors business daily which four biotechs are derisked buyable ahead of election day  pm nov    investors business daily synthetic biologics syn ceo jeffrey riley on q  results  earnings call transcript  pm nov    seeking alpha q synthetic biologics inc  am nov    edgar online  edg  q k ampliphi biosciences is making progress but a catalyst is lacking  am oct    seeking alpha loading more headlines at a glance synthetic biologics inc  medical center drive suite  rockville maryland  phone   industry pharmaceuticals sector health carelife sciences fiscal yearend  view sec filings revenue na net income m employees  annual report for syn newspressreleasecompanyussyn press releases on syn synthetic biologics to report second quarter  operational highlights and financial results on august    am july    pr newswire  prf synthetic biologics announces allowance of key us patent covering syn intended for the novel treatment of irritable bowel syndrome with constipation ibsc  am june    pr newswire  prf todays research reports on stocks to watch quantum corporation and synthetic biologics  am may    accesswire blog coverage synthetic biologics wins breakthrough therapy designation for its clostridium difficile infection candidate  am may    accesswire synthetic biologics reports first quarter  operational highlights and financial results  pm may    pr newswire  prf synthetic biologics to report first quarter  operational highlights and financial results on may    pm april    pr newswire  prf synthetic biologics reports preclinical data demonstrating syn provides protection from pertussis in neonatal animal study  am april    pr newswire  prf research reports initiation on biotech stocks  sangamo eyegate pharma synthetic biologics and regulus  am march    pr newswire  prf synthetic biologics to present at the th annual roth conference  am march    pr newswire  prf synthetic biologics reports  year end operational highlights and financial results  pm march    pr newswire  prf synthetic biologics to report  year end operational highlights and financial results on march    pm feb    pr newswire  prf technical reports on biotech stocks  progenics pharma intrexon synthetics biologics and nd century  am feb    pr newswire  prf synthetic biologics to present at the  bio ceo  investor conference  am feb    pr newswire  prf synthetic biologics confirms key features of pivotal phase b trial of syn pursuant to consultations with fda  pm jan    pr newswire  prf synthetic biologics syn ribaxamase achieves primary endpoint in phase b trial for c difficile infection cdi  am jan    pr newswire  prf research reports initiation on biotech stocks  arrowhead pharma intracellular therapies synthetic biologics and colucid pharma  am jan    pr newswire  prf synthetic biologics to present at the biotech showcase™  conference  am jan    pr newswire  prf synthetic biologics announces granting of us composition of matter patent for syn designed for the treatment and prevention of pertussis whooping cough  am dec    pr newswire  prf synthetic biologics announces participation in two upcoming investor conferences  am dec    pr newswire  prf synthetic biologics announces closing of public offering of common stock and warrants  pm nov    pr newswire  prf loading more headlines trending tickers quoteszigmancomposite vuzi quoteszigmancomposite jcp quoteszigmancomposite nugt quoteszigmancomposite jnug quoteszigmancomposite tlt x powered by log in  pm edt july   marketstatecountryus new york after marketstatecountryuk london closed marketstatecountryjp tokyo closed marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest pthe dark side of cruises pthe highest paid athletes in the world in one chart poj simpson made over  while in prison and won’t have to give any of it to the goldman family p trump to police dont be too nice phere are  coworkers you should avoid like the plague — especially in meetings ptop  most annoying people you may want to unfriend on facebook pthis is one person you should never unfriend on facebook p horrible ways typos could alter the course of your life ppaint your bathroom this color and boost your home’s selling price by  pamericans’ new badge of honor ‘i was blocked by a celebrity’ p weird things i found out about america in my first  hours pbeyond tesla  stocks driving the autonomous car revolution pthese  highly taxed companies need congress to finally act on tax reform pwatch out ‘kids’ are making the most money in this stock market p real ways for millennials to save money not by brownbagging and skipping starbucks p‘game of thrones’ this computer model predicts who will be killed off — or survive pthis basic balanced index fund is beating the hedge fund averages phere’s one trump fan who might make you some money pwhy it might be time to invest in the companies amazon is destroying pbitcoin investors things may get very ugly soon if this chart overlay is right loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice  syn stock price  synthetic biologics inc stock quote us nyse american  marketwatch sections watchlist signup • login search bulletin us europe asia fx rates futures range d d m m m y y dow    sp     nasdaq    globaldow    gold    oil    sp  movers algn  mhk  col  lyb  fls  mo  sbux  gt  latest newsall times eastern p updated the dark side of cruises p trump to police dont be too nice p updated the highest paid athletes in the world in one chart p updated oj simpson made over  while in prison and won’t have to give any of it to the goldman family p updated here are  coworkers you should avoid like the plague — especially in meetings p updated top  most annoying people you may want to unfriend on facebook p updated this is one person you should never unfriend on facebook p updated  horrible ways typos could alter the course of your life p updated paint your bathroom this color and boost your home’s selling price by  p updated americans’ new badge of honor ‘i was blocked by a celebrity’ to be replaced home investing quotes stocks united states syn overview compare quotes stock screener earnings calendar sectors syn us nyse american join td ameritrade find a broker synthetic biologics inc watchlist createsynalert after hours last updated jul    pm edt delayed quote     after hours volume  close chg chg     advanced charting d d m m m ytd y y all   vol advanced charting  vs avg volume k  day avg  m open  close   day lowhigh  day range   week lowhigh  your watchlist customize marketwatch have watchlists log in to see them here or sign up to get started create account … or log in symbol last chg chg  no items in watchlist there are currently no items in this watchlist add ticker to watchlist go to your watchlist no saved watchlists create a list of the investments you want to track create watchlist …or try this starter list uh oh something went wrong while loading watchlist go to watchlist recently viewed tickers no recent tickers visit a quote page and your recently viewed tickers will be displayed here search tickers overview profile news charts financials historical quotes analyst estimates options sec filings insiders key data open  day range     week range    market cap m shares outstanding m public float m beta  rev per employee na pe ratio na eps  yield na dividend na exdividend date na short interest m   of float shorted  average volume m performance  day   month   month  ytd   year  recent news marketwatch other dow jones wednesday’s biggest gaining  declining stocks nov   at  pm et by kate gibson adeona pharmaceuticals shares down  dec   at  am et by nick godt wednesdays biggest gaining and declining stocks apr   at  pm et by marketwatch adeona soars molecular insight retreats apr   at  pm et by val brickates kennedy adeona in spotlight indices sluggish apr   at  am et by val brickates kennedy monsanto’s shares engineered for growth jan   at  am et on barrons cfo moves penske automotive group iconix brand group agenus jun   at  pm et on the wall street journal up and down the ladder the latest comings and goings at pfizer gilead and… may   at  am et on the wall street journal biotechexec exits hurt more than the chemistry may   at  am et on barrons synthetic biologics set for catalysts mar   at  am et on barrons best buy swings to a loss gucci accuses guess of design knockoffs trademark squatting in china irks us retailers mar   at  am et on the wall street journal tpg sizes up surfwear specialist billabong feb   at  pm et on the wall street journal recent news other news press releases synthetic bio nabs us patent covering lead product candidate syn shares ahead  premarket synthetic bio nabs us patent covering lead product candidate syn shares ahead  premarket jun   at  am et on seeking alpha synthetic biologics inc syn makes further ip progress synthetic biologics inc nysemktsyn announced this morning that the us patent and trademark office uspto  jun   at  am et on smarteranalyst can the uptrend continue for synthetic biologics syn investors certainly have to be happy with synthetic biologics inc syn and its short term performance may   at  am et on zackscom synthetic biologics inc syn cuts through the red tape with big fda win for ribaxamase synthetic biologics inc nysemktsyn shares were rising almost  yesterday as the news took off  may   at  am et on smarteranalyst here’s why synthetic biologics inc syn shares skyrocket today nbsp investors in synthetic biologics inc nysemktsyn should be smiling from ear to ear today  may   at  am et on smarteranalyst synthetic bios ribaxamase a breakthrough therapy for prevention of c diff infection shares ahead  premarket synthetic bios ribaxamase a breakthrough therapy for prevention of c diff infection shares ahead  premarket may   at  am et on seeking alpha synthetic biologics syn ceo jeff riley on q  results  earnings call transcript synthetic biologics syn ceo jeff riley on q  results  earnings call transcript may   at  pm et on seeking alpha q synthetic biologics inc q synthetic biologics inc may   at  pm et on edgar online  edg  q k synthetic biologics syn presents at th annual roth conference mar   at  pm et on seeking alpha forget gilead buy these smallcap biotech stocks instead mar   at  pm et on zackscom synthetic biologics syn ceo jeffrey riley on q  results  earnings call transcript mar   at  pm et on seeking alpha msdc management lp buys yahoo coty novagold resources sells hrg group citigroup  feb   at  am et on gurufocuscom synthetic biologics syn investor presentation  slideshow feb   at  pm et on seeking alpha synthetic bio firms up ibsc trial design for lead product candidate syn shares ahead  after hours jan   at  pm et on seeking alpha synthetic biologics positive phase b results will move the needle jan   at  pm et on seeking alpha synthetic bios colead product candidate successful in midstage study shares ahead  premarket jan   at  am et on seeking alpha synthetic bio closes equity offering nov   at  pm et on seeking alpha ampliphi biosciences sweetens followon offering terms nov   at  pm et on seeking alpha could trump tax cut plans republican congress spur biotech ma nov   at  pm et on investors business daily which four biotechs are derisked buyable ahead of election day nov   at  pm et on investors business daily synthetic biologics to report second quarter  operational highlights and financial results on august   synthetic biologics to report second quarter  operational highlights and financial results on august   jul   at  am et on pr newswire  prf synthetic biologics announces allowance of key us patent covering syn intended for the novel treatment of irritable bowel syndrome with constipation ibsc synthetic biologics announces allowance of key us patent covering syn intended for the novel treatment of irritable bowel syndrome with constipation ibsc jun   at  am et on pr newswire  prf todays research reports on stocks to watch quantum corporation and synthetic biologics todays research reports on stocks to watch quantum corporation and synthetic biologics may   at  am et on accesswire blog coverage synthetic biologics wins breakthrough therapy designation for its clostridium difficile infection candidate blog coverage synthetic biologics wins breakthrough therapy designation for its clostridium difficile infection candidate may   at  am et on accesswire synthetic biologics reports first quarter  operational highlights and financial results synthetic biologics reports first quarter  operational highlights and financial results may   at  pm et on pr newswire  prf synthetic biologics to report first quarter  operational highlights and financial results on may   apr   at  pm et on pr newswire  prf synthetic biologics reports preclinical data demonstrating syn provides protection from pertussis in neonatal animal study apr   at  am et on pr newswire  prf research reports initiation on biotech stocks  sangamo eyegate pharma synthetic biologics and regulus mar   at  am et on pr newswire  prf synthetic biologics to present at the th annual roth conference mar   at  am et on pr newswire  prf synthetic biologics reports  year end operational highlights and financial results mar   at  pm et on pr newswire  prf synthetic biologics to report  year end operational highlights and financial results on march   feb   at  pm et on pr newswire  prf technical reports on biotech stocks  progenics pharma intrexon synthetics biologics and nd century feb   at  am et on pr newswire  prf synthetic biologics to present at the  bio ceo  investor conference feb   at  am et on pr newswire  prf synthetic biologics confirms key features of pivotal phase b trial of syn pursuant to consultations with fda jan   at  pm et on pr newswire  prf synthetic biologics syn ribaxamase achieves primary endpoint in phase b trial for c difficile infection cdi jan   at  am et on pr newswire  prf research reports initiation on biotech stocks  arrowhead pharma intracellular therapies synthetic biologics and colucid pharma jan   at  am et on pr newswire  prf synthetic biologics to present at the biotech showcase™  conference jan   at  am et on pr newswire  prf synthetic biologics announces granting of us composition of matter patent for syn designed for the treatment and prevention of pertussis whooping cough dec   at  am et on pr newswire  prf synthetic biologics announces participation in two upcoming investor conferences dec   at  am et on pr newswire  prf synthetic biologics announces closing of public offering of common stock and warrants nov   at  am et on pr newswire  prf synthetic biologics inc synthetic biologics inc is a clinical stage company which engages in the development of therapeutics to preserve the microbiome to protect and restore the health of patients its product portfolio includes syn and syn the syn which is intended to reduce the impact of methaneproducing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation the syn which is designed to protect the gut microbiome from the effects of certain commonly used intravenous iv antibiotics for the prevention of c difficile infection antibioticassociated diarrhea and the emergence of antimicrobial resistance the company was founded by steven h kanzer in january  and is headquartered in rockville md see full profile analyst ratings sell under hold over buy number of ratings  full ratings  biotechs with binary events coming this year jan   at  pm et on benzingacom competitors name chg  market cap biogen inc  b momenta pharmaceuticals inc  b astrazeneca plc adr  b abbott laboratories  b pfizer inc  b competitor data provided by partner content trending tickers powered by dvax  mo  clvs  ssti  imgn  advanced search stocks columns authors topics no results found video center learn morestoryful a division of news corp which owns marketwatch is a leading social media services company headquartered in dublin ireland storyful combines world class journalism with industryleading technology to discover verify and acquire original content and provide the ontheground sources news and media organizations need to tell the stories that matter to their audience facebook autocomplete demo post a rating  month price target   home trending sign up log in analyst ranking   name measured ratings sucess rate avg return  mizuho      credit suisse      jefferies      cantor fitzgerald      bank of america merrill lynch      jmp securities      goldman sachs      raymond james      fbr capital markets      william blair     microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft synthetic biologics inc syn company profile  reuterscom x edition united states africa américa latina عربي argentina brasil canada  deutschland españa france india italia  méxico россия united kingdom united states profile synthetic biologics inc syn related topics stocksstock screenerhealthcarebiotechnology  medical research overview news key developments people charts financials analysts research pulse syn on american stock exchange usd  jul  change  chg   prev close  open  days high  days low  volume  avg vol  wk high  wk low  full description synthetic biologics inc incorporated on december   is a clinicalstage company the company is engaged in developing therapeutics to protect the gut microbiome while targeting pathogenspecific diseases the companys lead product candidates in phase ii development are syn which is intended to reduce the impact of methaneproducing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation ibsc and syn which is designed to protect the gut microbiome gastrointestinal gi microflora from the effects of certain commonly used intravenous iv antibiotics for the prevention of c difficile infection cdi and antibioticassociated diarrhea aad its other product candidates include syn syn syn syn and syn the company is also developing preclinicalstage monoclonal antibody therapies for the prevention and treatment of pertussis and discoverystage biotherapeutics for the treatment of phenylketonuria pku its ibsc and cdiaad programs are focused on protecting the gut microbiome or gut florasynthe companys product candidate syn is intended to act primarily in the intestinal lumen while avoiding systemic absorption thereby targeting the cause of ibsc not just the patients symptoms the company has completed phase i clinical trial of synsynthe companys product candidate syn is an oral prophylactic therapy the company has completed phase i clinical trial of synsynthe companys syn product is used for the prevention of cdi and aad preclinical work is ongoing to determine the ability of syn to protect the gut microbiome and degrade oral betalactam antibiotics syn comprises a reformulated version of syn for use with oral betalactam antibiotics versus iv betalactam antibioticssynthe companys syn product is used for the prevention of cdi and aad the development of syn is in the discovery stage syn is intended to be an oral prophylactic therapy designed to degrade iv carbapenem antibiotics a third class of betalactam antibiotics within the gi tract and maintain the natural balance of the gut microbiomesynthe companys syn product is used for the prevention of pertussis whooping cough the development of syn is in preclinicalstagesynthe companys syn product is used for the treatment of phenylketonuria pku the development of syn is in discoverystagesynthe companys syn is used for the treatment of oral intestinal alkaline phosphatase the development of syn is in the discoverystage syn is being developed as a modifiedrelease oral dosage form of intestinal alkaline phosphatase iap » full overview of syn company address synthetic biologics inc  detroit st ste ann arbor   mi    p f  company web links home page officers  directors name compensation jeffrey kraws  jeffrey riley  steven shallcross  scott tarriff  jeffrey wolf  » more officers  directors synthetic biologics inc news briefsynthetic biologics announces allowance of us patent covering syn jun   briefsynthetic biologics receives fda breakthrough therapy designation for syn may   briefsynthetic biologics qtrly loss per share  may   briefsynthetic biologics reports preclinical data on syn apr   » more syn news related topics stocksstock screenerhealthcarebiotechnology  medical research synthetic biologics inc company profile  bloomberg feedback synthetic biologics inc public company company profile sector health care industry biotech  pharma subindustry specialty pharma synthetic biologics inc is a clinical stage company developing therapeutics which protect microbiomes and target pathogenspecific diseases the company develops drugs that are designed to reduce the impact of methaneproducing organisms to help treat the cause of ibsc and designed to protect microbiomes and prevent cdi during iv antibiotic use corporate information address  medical center drive suite  rockville md  united states phone  fax  web url wwwsyntheticbiologicscom board members chairman company presidentceo company jeffrey riley synthetic biologics inc board members company scott tarriff eagle pharmaceuticals incde jeffrey wolf heat biologics inc from the web press releases synthetic biologics to report second quarter  operational highlights and financial results on august    day ago synthetic biologics announces allowance of key us patent covering syn intended for the novel treatment of irritable bowel jun   syn ribaxamase receives breakthrough therapy designation from us food and drug administration for prevention of clostri may   synthetic biologics reports first quarter  operational highlights and financial results may   synthetic biologics to report first quarter  operational highlights and financial results on may   apr   synthetic biologics reports preclinical data demonstrating syn provides protection from pertussis in neonatal animal study apr   avivagen announces results from its annual and special meeting of shareholders apr   synthetic biologics to present at the th annual roth conference mar   key executives jeffrey lucero riley jeff presidentceo steven a shallcross cfotreasurersecretary joseph sliman chief medical officer sponsored financial commentaries more from the web home news top headlines most popular exclusive law entrepreneurs leaders economy environment science sports markets magazine pursuits magazine bloomberg visual data bloomberg best and worst for comments or complaints about news coverage click here regions us china europe asia uk  ireland australia  new zealand canada india  pakistan japan africa eastern europe latin america middle east markets commodities currencies bonds stocks energy markets municipal bonds emerging markets funds islamic finance industries energy technology real estate finance health care transportation insurance retail media manufacturing quick market data stocks stock futures world indexes americas europe middle east  africa asiapacific gainers  losers earnings calendar industry leaders currencies americas europe middle east  africa asiapacific foreign exchange cross rates fx fixings currency converter forex trading videos commodities energy prices metals prices agricultural prices rates  bonds us treasuries uk gilts germany bunds japan bonds australia bonds bloomberg bond indexes corporate bonds consumer rates economic calendar watchlist european debt crisis symbol search the market now personal finance top headlines saving  investing real estate retirement planning financial advisers taxes blog ventured  gained real cost of money gallery calculators watchlist portfolio tracker tech top headlines social media mobile  wireless web enterprise tech tv games  movies apple tech deals global tech slideshows videos us politics sustainability top headlines energy corporate sustainability policy natural resources health  population slideshows videos blog the grid luxury top headlines autos billionaires living property travel well spent loot blog pursuits magazine videos tv live tv channel finder personalities apple tv ipad app schedule us asia europe shows surveillance market makers lunch money street smart bloomberg west game changers video must see latest live tv shows playlist radio live radio shows schedule personalities podcasts bloomberg brief featured podcasts and new shows bloomberg view masters in business first word surveillance bloomberg advantage in the loop bloomberg law taking stock bloomberg best more podcasts blogs global tech the grid loot the market now political capital tech deals ventured and gained opinion my saved registration sign in bloombergcom businessweekcom company about blog careers diversity  inclusion news mission philanthropy  engagement press room procurement sustainability products financial products bloomberg professional service bloomberg anywhere bloomberg tradebook bloomberg briefs bloomberg indexes bloomberg sef service center customer support enterprise products enterprise solutions trading solutions industry products bloomberg bna bloomberg government bloomberg law bloomberg link bloomberg new energy finance bloomberg sports content licensing bloomberg anywhere mobile apps bloomberg visual data flashratings  contact us facebook autocomplete demo post a rating  month price target   trending sign up log in contact flashratings your emotional state excited confused worried upset panicked angry synthetic biologics inc company information  drugscom skip to content search all allconsumerprofessionalpill idinteractionsnewsfda alertsapprovalspipelineclinical trialscare notesencyclopediadictionarynatural products browse all medications a b c d e f g h i j k l m n o p q r s t u v w x y z advanced search topics  tools facebook twitter google plus sign in sign in register menu home › pharmaceutical companies › synthetic biologics inc print share synthetic biologics inc address synthetic biologics inc  medical center dr suite  rockville md contact detailsphone  website wwwsyntheticbiologicscomcareers wwwsyntheticbiologicscomabout adeona pharmaceuticals has changed its name to synthetic biologics inc this is to better reflects its new focus on genebased therapies december  latest drug information updates vosevi vosevi sofosbuvir  velpatasvir  voxilaprevir is a singletablet regimen for the treatment of adults withnerlynx nerlynx neratinib is a tyrosine kinase inhibitor for the extended adjuvant treatment of patients with earlytremfya tremfya guselkumab is an interleukin blocker indicated for the treatment of adult patients withbevyxxa bevyxxa betrixaban is an oral oncedaily factor xa inhibitor anticoagulant for the extendeddurationrituxan hycela rituxan hycela rituximab and hyaluronidase human is a subcutaneous monoclonal antibody and hyaluronidasebaxdela baxdela delafloxacin is a fluoroquinolone antibacterial indicated for the treatment of acute bacterial skin more drug information updates drugscom mobile apps the easiest way to lookup drug information identify pills check interactions and set up your own personal medication records available for android and ios devices explore apps support help center frequent questions sitemap contact us about about drugscom advertising policy content submissions drugscom blog terms  privacy editorial policy privacy policy terms of use attribution  citations facebook twitter google plus youtube rss feed subscribe to receive email notifications whenever new articles are published drugscom provides accurate and independent information on more than  prescription drugs overthecounter medicines and natural products this material is provided for educational purposes only and is not intended for medical advice diagnosis or treatment data sources include micromedex® updated july th  cerner multum™ updated july th  wolters kluwer™ updated july th  and others to view content sources and attributions please refer to our editorial policy third party advertising we comply with the honcode standard for trustworthy health information  verify here copyright   drugscom all rights reserved share on facebook share on twitter share on googleplus email to a friend hide syn  stock quote for synthetic biologics inc  msn money msn back to msn home money web search sign in change language  content américa latina español argentina español australia english belgië nederlands belgique français brasil português canada english canada français chile español colombia español danmark dansk deutschland deutsch españa español france français india english indonesia bahasa indonesia ireland english italia italiano malaysia english méxico español nederland nederlands new zealand english norge norsk bokmål österreich deutsch perú español philippines english polska polski portugal português schweiz deutsch singapore english south africa english suisse français suomi suomi sverige svenska türkiye türkçe united arab emirates english united kingdom english united states english united states español venezuela español việt nam tiếng việt ελλάδα ελληνικά россия pусский ישראל עברית‏ الإمارات العربية المتحدة العربية‏ المملكة العربية السعودية العربية‏ مصر العربية‏ ไทย ไทย 한국 한국어      語   switch to latino español feedback help adchoices synthetic biologics inc amex syn us markets closed adchoices  ▲   after hours     july    pm edt delayed  minutes source nasdaq currency in usd save summary financials analysis options ownership company history related open  previous close  volume avg k m days range  wk range  market cap m dividend rate  yield  beta  shares outstanding m pe ratio eps  recent news synthetic biologics inc syn ihadvfncom  detailed examination of the global phenylketonuria pipeline therapeutics development insights h  whatech  synthetic biologics inc nysemktsyn lowered to hold at zacks investment research breeze  analysts recommendations synthetic biologics inc syn newsoraclecom  ubs oconnor llc holds stake in synthetic biologics inc syn breeze  synthetic biologics nysemktsyn receives media impact rating of  bns  in volatile markets do analysts think you should buy synthetic biologics inc syn desotoedgecom  somewhat positive press coverage extremely likely to impact synthetic biologics syn share price themarketsdailycom  new patent to cover treatment for ibsc healio  synthetic biologics receives patent office allowance for active agent in ibsc treatment —  key notes beckersasccom  synthetic biologics receives us patent covering syn intended for novel treatment of ibsc pharmabiz  synthetic biologics announces allowance of key us patent cover  wfmjcom news weather sports for youngstownwarren ohio wfmj  phenylalanine  hydroxylase therapeutic pipeline h  drugs diagnostics vaccines and preventive technologies green mountain outlook  synthetic biologics announces allowance of key us patent cover  kait jonesboro ar  region  news weather sports  abc kaitcom  briefsynthetic biologics announces allowance of us patent covering syn reuters  synthetic biologics inc syn makes further ip progress wwwsmarteranalystcom  synthetic biologics announces allowance of key us patent cover  kfda  newschannel   amarillo news weather sports kfda newschannel   synthetic biologics announces allowance of key us patent cover  kctv kctv news  adchoices adchoices adchoices markets dow dow ▲    last updated time   pm edt markets nasdaq nasdaq ▼    ftse  ftse  ▼    nyse composite nyse composite ▼    adchoices feedback send feedback provide feedback report a problem we appreciate your input select a category im having problems with top destinations im having issues searching im having problems with featured apps i see an error in the content other how we can improve please give an overall site rating submit close privacy statement help help  support flashratings  principles facebook autocomplete demo post a rating  month price target   trending sign up log in flashratings principles  flashratings mission is to provide you  the investor  with as much honest and professional research on your investments as possible  we believe its much better to get a multitude of credible opinions on an investment than to arbitrarily follow any single advisor  be it your banker a friend or a tv pundit  flashratings does not provide advice our job is to accurately and objectively report on analysts credible research and opinions the only advice flashratings will ever give you is to absorb as much fundamental research and different opinions as possible and make your own decisions  flashratings favors covering analysts with proven track records but will cover all analysts as long as their research is honest and professional sign up »